Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 29;14(9):2236.
doi: 10.3390/cancers14092236.

The Prognostic Value of Eight Comorbidity Indices in Older Patients with Cancer: The ELCAPA Cohort Study

Affiliations

The Prognostic Value of Eight Comorbidity Indices in Older Patients with Cancer: The ELCAPA Cohort Study

Florence Canoui-Poitrine et al. Cancers (Basel). .

Abstract

Background: A prognostic assessment is crucial for making cancer treatment decisions in older patients. We assessed the prognostic performance (relative to one-year mortality) of eight comorbidity indices in a cohort of older patients with cancer. Methods: We studied patients with cancer aged ≥70 included in the Elderly Cancer Patient (ELCAPA) cohort between 2007 and 2010. We assessed seven nonspecific indices (Charlson Comorbidity Index (CCI), three modified versions of the CCI, the Elixhauser Comorbidity Index, the Gagne index, and the Cumulative Illness Rating Scale for Geriatrics (CIRS-G)) and the National Cancer Institute Comorbidity Index. Results: Overall, 510 patients were included. Among patients with nonmetastatic cancer, all the comorbidity indices were independently associated with 1-year mortality (adjusted hazard ratios (aHRs) of 1.44 to 2.51 for one standard deviation increment; p < 0.05 for all) and had very good discriminant ability (Harrell’s C > 0.8 for the eight indices), but were poorly calibrated. Among patients with metastatic cancer, only the CIRS-G was independently associated with 1-year mortality (aHR (95% confidence interval): 1.26 [1.06−1.50]). Discriminant ability was moderate (0.61 to 0.70) for the subsets of patients with metastatic cancer and colorectal cancer. Conclusion: Comorbidity indices had strong prognostic value and discriminative ability for one-year mortality in older patients with nonmetastatic cancer, although calibration was poor. In older patients with metastatic cancer, only the CIRS-G was predictive of one-year mortality.

Keywords: cancer; comorbidities; indices; mortality; older patients.

PubMed Disclaimer

Conflict of interest statement

None of the authors has any conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Study flow diagram: 26 missing items of data for the first 644 patients: tumor site (n = 9), age (n = 1), vital status (n = 4), metastasis (n = 16). Some patients lacked more than one item of data.
Figure 2
Figure 2
Calibration slopes for (A) the original CCI, (B) the Gagne index, (C) the ECI, and (D) the CIRS-G. Smoothed pseudovalues (red line) with 95% CI plotted against predicted event probabilities at one year. The green line is the line of identity, denoting perfect calibration. CCI indicates Charlson Comorbidity Index; ECi indicates Elixhauser-van Walraven Comorbidity Index; CIRG-S indicates Cumulative Illness Rating Scale for Geriatrics.

References

    1. Dyba T., Randi G., Bray F., Martos C., Giusti F., Nicholson N., Gavin A., Flego M., Neamtiu L., Dimitrova N., et al. The European cancer burden in 2020: Incidence and mortality estimates for 40 countries and 25 major cancers. Eur. J. Cancer. 2021;157:308–347. doi: 10.1016/j.ejca.2021.07.039. - DOI - PMC - PubMed
    1. Edwards B.K., Noone A.M., Mariotto A.B., Simard E.P., Boscoe F.P., Henley S.J., Jemal A., Cho H., Anderson R.N., Kohler B.A., et al. Annual Report to the Nation on the status of cancer, 1975–2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2014;120:1290–1314. doi: 10.1002/cncr.28509. - DOI - PMC - PubMed
    1. Terret C., Castel-Kremer E., Albrand G., Droz J.P. Effects of comorbidity on screening and early diagnosis of cancer in elderly people. Lancet Oncol. 2009;10:80–87. doi: 10.1016/S1470-2045(08)70336-X. - DOI - PubMed
    1. Corkum M., Urquhart R., Kendell C., Burge F., Porter G., Johnston G. Impact of comorbidity and healthcare utilization on colorectal cancer stage at diagnosis: Literature review. Cancer Causes Control. 2012;23:213–220. doi: 10.1007/s10552-011-9875-8. - DOI - PMC - PubMed
    1. Lee L., Cheung W.Y., Atkinson E., Krzyzanowska M.K. Impact of comorbidity on chemotherapy use and outcomes in solid tumors: A systematic review. J. Clin. Oncol. 2011;29:106–117. doi: 10.1200/JCO.2010.31.3049. - DOI - PubMed

LinkOut - more resources